Bharathi Raju, MD
Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1720078843
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,186 of the $23,886 with a category attached, or 63.6%. 60 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 26.5% of the total. Reporting peaked in 2020 at $6,407 and has fallen 72.5% since, to $1,763 in 2025.
Across 1,019 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$6K
- Insulet Corporation$3K
- Novo Nordisk$2K
- Abbott$2K
- Lilly USA, LLC$1K
- Amgen$920
- plus $9K from 54 others
Across 23 payments — averaging $1259.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$29K
What the payments were for
- Speaking & faculty fees$8,70036%
- Food & beverage$15,18664%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$4,700
- Omnipod$2,400
- t:slim X2 insulin pump$1,600
How this compares
$23,886 in reported general payments places this provider in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 495 | $937,758 |
| JardianceEmpagliflozin | 475 | $505,507 |
| MounjaroTirzepatide | 265 | $417,301 |
| TrulicityDulaglutide | 222 | $299,903 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 159 | $234,107 |
| Humalog Kwikpen U-200Insulin Lispro | 88 | $213,573 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 146 | $174,237 |
| Tresiba Flextouch U-100Insulin Degludec | 182 | $146,876 |
| Tresiba Flextouch U-200Insulin Degludec | 115 | $143,354 |
| ForteoTeriparatide | 22 | $92,490 |
| Novolog FlexpenInsulin Aspart | 204 | $88,560 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $85,572 |
| Humalog Kwikpen U-100Insulin Lispro | 169 | $84,614 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 119 | $82,116 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 97 | $75,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Wegovy | $2,064 | $1,028,260560 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo | $1,309 | $809,693509 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $463 | $656,826652 claims |
| MerckJanuvia, Janumet Xr | $148 | $103,80295 claims |
| AmgenProlia | $920 | $62,84736 claims |
| AstraZenecaFarxiga | $313 | $31,89629 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $435 | $29,42725 claims |
| BayerKerendia | $453 | $23,56823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Louis
- Janet McGillSaint Louis$212K
- Farid RomanSaint Louis$62K
- Kathryn DiemerSaint Louis$57K
- Julie SilversteinSaint Louis$49K
- Michael WhyteSaint Louis$40K
- Alexis McKeeSaint Louis$37K
- Sandeep DhindsaSaint Louis$36K
- Thomas NickolasSaint Louis$35K
- K ThampySaint Louis$35K
- Garry TobinSaint Louis$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.